PTC Therapeutics, Inc. (NASDAQ:PTCT) was the recipient of some unusual options trading on Wednesday. Traders purchased 3,043 put options on the company. This is an increase of approximately 2,154% compared to the average daily volume of 135 put options.
PTC Therapeutics (NASDAQ:PTCT) opened at $23.29 on Monday. The company has a market capitalization of $966.30, a PE ratio of -8.06 and a beta of 1.23. PTC Therapeutics has a one year low of $8.12 and a one year high of $23.71. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.97 and a current ratio of 3.08.
PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.67) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.66) by ($0.01). PTC Therapeutics had a negative return on equity of 75.19% and a negative net margin of 75.64%. sell-side analysts expect that PTC Therapeutics will post -2.01 EPS for the current year.
A number of research firms have issued reports on PTCT. Zacks Investment Research downgraded PTC Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. ValuEngine upgraded PTC Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, January 9th. Barclays reduced their price objective on PTC Therapeutics from $22.00 to $15.00 and set an “equal weight” rating on the stock in a research note on Friday, September 29th. Royal Bank of Canada restated a “sector perform” rating on shares of PTC Therapeutics in a research note on Friday, September 29th. Finally, Credit Suisse Group restated an “outperform” rating and set a $25.00 price objective on shares of PTC Therapeutics in a research note on Tuesday, September 26th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $19.14.
In other PTC Therapeutics news, CEO Stuart Walter Peltz sold 2,230 shares of the business’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $18.03, for a total transaction of $40,206.90. Following the completion of the sale, the chief executive officer now owns 26,646 shares of the company’s stock, valued at $480,427.38. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders have sold 2,719 shares of company stock valued at $48,848. 8.10% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of the business. Macquarie Group Ltd. acquired a new position in shares of PTC Therapeutics in the third quarter worth about $102,000. Public Employees Retirement System of Ohio acquired a new position in shares of PTC Therapeutics in the second quarter worth about $142,000. Quantbot Technologies LP acquired a new position in shares of PTC Therapeutics in the third quarter worth about $150,000. Prudential Financial Inc. acquired a new position in shares of PTC Therapeutics in the second quarter worth about $201,000. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of PTC Therapeutics in the third quarter worth about $229,000. Institutional investors own 86.12% of the company’s stock.
WARNING: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/15/ptc-therapeutics-sees-unusually-large-options-volume-ptct.html.
PTC Therapeutics Company Profile
PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.